RYONCIL (remestemcel-L)

About Mesoblast

Mesoblast is a pioneering Australian biotechnology company with a mission to transform patient outcomes through its proprietary allogeneic mesenchymal lineage cell technology platform. Its key achievement is the FDA approval and commercialization of RYONCIL for pediatric steroid-refractory acute graft-versus-host disease, marking it as a first-in-class therapy. The company's strategy leverages this validated platform to expand into large market opportunities in chronic low back pain, heart failure, and other inflammatory conditions, aiming to establish a new paradigm in regenerative medicine.

Therapeutic Areas